Managing antidepressant treatment in pregnancy and puerperium. Careful with that axe, Eugene

Expert Opinion on Drug Safety

Volumn 14, Issue 7, 2015, Pages 1011-1014

  Gentile, Salvatore ^a,b  

^a ASL Salerno   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antidepressants; Breastfeeding; Pregnancy; Safety

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

AUTISM; BREAST MILK; CLINICAL PRACTICE; CONGENITAL MALFORMATION; FETUS DEVELOPMENT; HUMAN; PATIENT SAFETY; PREGNANCY; PSYCHOPHARMACOTHERAPY; PUERPERAL DEPRESSION; PUERPERIUM; REVIEW; RISK ASSESSMENT; TERATOGENESIS; ABNORMALITIES, DRUG-INDUCED; ADVERSE EFFECTS; BREAST FEEDING; DEPRESSIVE DISORDER; FEMALE; PERINATAL CARE; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; BREAST FEEDING; DEPRESSIVE DISORDER; FEMALE; HUMANS; PERINATAL CARE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT;

EID: 84931837834     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1037273     Document Type: Review

References (15)

1. Gentile S. On categorizing gestational birth, and neonatal complications following late in utero exposure to antidepressants. The prenatal antidepressant exposure syndrome. CNS Spectr 2010;15(3):167-85
2. Gentile S. SRI-induced perinatal complications. Paediatr Drugs 2007;9(12):97-106
3. Weisskopf E, Fischer CJ, Graz MB, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opin Drug Saf 2015;14(3):413-27
4. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: A population based cohort study. Br Med J 2009;339:b3569
5. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin reuptake inhibitors during early pregnancy and the risk of congenital malformations: Updated analysis. Clin Epidemiol 2010;2:29-36
6. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Def Res Part B 2008;83:68-76
7. Yazdy MM, Mitchel AA, Louik C, et al. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. Epidemiology 2014;25:859-65
8. Berard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol 2015. [Epub ahead of print].
9. National Teratology Information Service. Treatment of depression in pregnancy. National Teratology Information Service, Regional Drugs and Therapeutics Centre. Newcastle upon Tyne; England: 2005
10. National Institute for Health and Clinical Excellence. Antenatal and postnatal mental health, national clinical practice guideline number 45. 2007. Available from: http://www.nice. org.uk/nicemedia/pdf
11. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Exp Opin Drug Saf 2014;13(2):207-25
12. Gentile S. SSRI exposure during early pregnancy and risk of birth defects. Acta Psychiatr Scand 2011;123(4):266-75
13. Gentile S, Rossi A, Bellantuono C. SSRIs during breastfeeding: Spotlight on milk-to-plasma ratio. Arch Womens Ment Health 2007;10(2):39-51
14. Berle J, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev 2011;7:28-34.
15. Gentile S. Use of contemporary antidepressants during breastfeeding. A proposal for a specific safety index. Drug Saf 2007;30(2):107-1